<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300296</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457S12201</org_study_id>
    <nct_id>NCT04300296</nct_id>
  </id_info>
  <brief_title>PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus</brief_title>
  <acronym>PRELUDE</acronym>
  <official_title>A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - PRELUDE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the proof of concept study is to elucidate the efficacy of secukinumab&#xD;
      in the treatment of adult patients with biopsy-proven lichen planus not adequately controlled&#xD;
      by topical therapies, and to assess the safety and tolerability over 32 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 32-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group&#xD;
      trial assessing the efficacy and safety of secukinumab 300 mg in two different dosing&#xD;
      regimens: every 4 weeks (Q4W) and every 2 weeks (Q2W) in approximately 108 patients with&#xD;
      biopsy-proven forms of lichen planus.&#xD;
&#xD;
      There will be a screening period (up to 4 weeks prior to baseline), a treatment period 1&#xD;
      (baseline to Week 16), a treatment period 2 (Week 16 to Week 32) and a follow-up period (8&#xD;
      weeks after Week 32).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 27, 2020</start_date>
  <completion_date type="Anticipated">April 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>PoC study, 32-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial assessing the efficacy and safety of secukinumab 300 mg in two different dosing regimens in 108 patients with biopsy-proven forms of lichen planus.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Investigator Global Assessment (IGA) score of 2 or less at week 16</measure>
    <time_frame>week 16</time_frame>
    <description>IGA of 2 or less&#xD;
The IGA score is based on a 5-point acne severity scale from zero (clear) to 4 (severe). Successful outcome is at least a 2-point reduction in IGA score from baseline to 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with 2 IGA points improvement from baseline</measure>
    <time_frame>week 16 and 32</time_frame>
    <description>2 IGA points improvement from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Achievement of IGA score 0 or 1 at weeks 16 and 32 2</measure>
    <time_frame>week 16 and 32</time_frame>
    <description>Achievement of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>baseline, weeks 16 and 32</time_frame>
    <description>Absolute and relative change from baseline&#xD;
0-1 = No effect on patient's life, 2-5 = Small effect, 6-10 = Moderate effect, 11-20 = Very large effect, 21-30 = Extremely large effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>week 32</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris</condition>
  <arm_group>
    <arm_group_label>Cutaneous lichen planus secukinumab 300mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 300 mg every 4 weeks provided in 1ml PFS in cutaneous lichen planus patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cutaneous lichen planus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in 1ml PFS in cutaneous lichen patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucosal lichen planus secukinumab 300 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 300 mg every 4 weeks provided in 1 ml PFS in mucosal lichen planus patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucosal lichen planus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 ml PFS in mucosal lichen planus patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lichen planopilaris secukinumab 300 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 300 mg every 4weeks provided in 1ml PFS in lichen planopilaris patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lichen planopilaris placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in 1ml PFS in lichen planopilaris patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cutaneous lichen planus secukinumab 300 mg Q4W</intervention_name>
    <description>All cutaneous lichen planus patients assigned to active secukinumab will receive 2x 1ml PFS at randomization, Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At Week 16, they will stay on the weekly placebo dosis and monthly secukinumab until Week 32.</description>
    <arm_group_label>Cutaneous lichen planus secukinumab 300mg Q4W</arm_group_label>
    <other_name>Secukinumab 300 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cutaneous lichen planus placebo</intervention_name>
    <description>All cutaneous LP patients assigned to placebo will receive 2x 1ml placebo PFS at randomization , Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At Week 16, they will be switched to secukinumab (if no spontanoues remision) for weekly dosis until Week 20, then bi-weekly injection of secukinumab until Week 30</description>
    <arm_group_label>Cutaneous lichen planus placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucosal lichen planus placebo</intervention_name>
    <description>All mucosal lichen planus patients assigned to placebo will receive 2x 1ml placebo PFS at randomization , Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At Week 16, they will be switched to secukinumab (if no spontaneous remission) for weekly dosis until Week 20, then bi-weekly injection of secukinumab until Week 30</description>
    <arm_group_label>Mucosal lichen planus placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lichen planopilaris placebo</intervention_name>
    <description>All lichen planopilaris patients assigned to placebo will receive 2x 1ml placebo PFS at randomization , Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At Week 16, they will be switched to secukinumab (if no spontanoues remision) for weekly dosis until week 20, then bi-weekly injection of secukinumab until Week 30</description>
    <arm_group_label>Lichen planopilaris placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucosal lichen planus secukinumab 300 mg Q4W</intervention_name>
    <description>All mucosal lichen planus patients assigned to active secukinumab will receive 2x 1ml PFS at randomization , Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At week 16, they will stay on the weekly placebo dosis and monthly secukinumab until Week 30.</description>
    <arm_group_label>Mucosal lichen planus secukinumab 300 mg Q4W</arm_group_label>
    <other_name>Secukinumab 300 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lichen planopilaris secukinumab 300 mg Q4W</intervention_name>
    <description>All lichen planopilaris LP patients assigned to active secukinumab will receive 2x 1ml PFS at randomization , Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At Week 16, they will stay on the weekly placebo dosis and monthly secukinumab until Week 30.</description>
    <arm_group_label>Lichen planopilaris secukinumab 300 mg Q4W</arm_group_label>
    <other_name>Secukinumab 300mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          2. Female and male patients ≥ 18 years of age.&#xD;
&#xD;
          3. Subjects must have biopsy-confirmed forms of cutaneous lichen planus (CLP), mucosal&#xD;
             lichen planus (MLP), or active lichen planopilaris (LPP) eligible for systemic therapy&#xD;
             based on the following criteria:&#xD;
&#xD;
               -  rated IGA of ≥ 3 (moderate or severe) AND&#xD;
&#xD;
               -  inadequate response to topical corticosteroids of high-ultrahigh potency in the&#xD;
                  opinion of the investigator.&#xD;
&#xD;
          4. If using any of the allowed topical treatments on the affected areas, the dose and&#xD;
             application frequency should remain stable for 2 weeks prior to randomization and&#xD;
             until Week 16.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical history suspicious for lichenoid drug eruption.&#xD;
&#xD;
          2. Lichen planus pigmentosus.&#xD;
&#xD;
          3. Clinical picture or history suspicious of paraneoplastic mucosal lichen planus.&#xD;
&#xD;
          4. Subjects whose lichen planus is a predominantly bullous variant.&#xD;
&#xD;
          5. Mucosal LP of the oral cavity or gastrointestinal involvement requiring the patient to&#xD;
             use parenteral nutrition or feeding tube.&#xD;
&#xD;
          6. Clinical picture of scarring alopecia without active inflammation.&#xD;
&#xD;
          7. Clinical picture of burnt-out cicatricial alopecia (alopecia of Brocque).&#xD;
&#xD;
          8. Patients diagnosed with frontal fibrosing alopecia (FFA) without active patches of LPP&#xD;
&#xD;
          9. Clinical picture of LPP in patients who have already failed 3 or more systemic&#xD;
             immunosuppressive or immunomodulatory agents (e.g. systemic steroids,&#xD;
             hydroxychloroquine, cyclosporine, methotrexate and mycophenolate mofetil).&#xD;
&#xD;
         10. Currently enrolled in any other clinical trial involving any investigational agent or&#xD;
             device.&#xD;
&#xD;
         11. Previous exposure to any other biologic drug directly targeting IL-17A or IL-17RA&#xD;
             (e.g. secukinumab, ixekizumab or brodalumab) or IL-23/p19 (e.g. tildrakizumab,&#xD;
             guselkumab, risankizumab).&#xD;
&#xD;
         12. Diagnosis of active infectious diseases of the skin, scalp or mucosa (for example&#xD;
             bacterial, viral or fungal infections of the mouth) that may interfere with the&#xD;
             assessment of the study disease or require treatment with prohibited medications.&#xD;
&#xD;
         13. Diagnosis of active inflammatory diseases of the skin, scalp or mucosa other than&#xD;
             lichen planus that may interfere with the assessment of the study disease or require&#xD;
             treatment with prohibited medications.&#xD;
&#xD;
         14. Presence of any other skin condition that may affect the evaluations of the study&#xD;
             disease.&#xD;
&#xD;
         15. Underlying conditions (including, but not limited to metabolic, hematologic, renal,&#xD;
             hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal)&#xD;
             and/or presence of laboratory abnormalities which in the opinion of the investigator&#xD;
             significantly immunocompromises the subject and/or places the subject at unacceptable&#xD;
             risk for receiving an immunomodulatory therapy.&#xD;
&#xD;
         16. Current, severe, progressive or uncontrolled diseases that render the patient&#xD;
             unsuitable for the trial, including any medical or psychiatric condition that, in the&#xD;
             Investigator's opinion, would preclude the participant from adhering to the protocol&#xD;
             or completing the study per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025 1737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chambray les Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille Cedex 05</city>
        <zip>13885</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bramsche</city>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lichen planus</keyword>
  <keyword>CLP</keyword>
  <keyword>MLP</keyword>
  <keyword>LPP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

